September 12, 2018: LivaNova PLC announced the first implanted patient and official launch of a global registry to evaluate the use of LivaNova’s Vagus Nerve Stimulation Therapy® (VNS Therapy) System for patients with drug-resistant epilepsy (DRE), which affects nearly one in three people with epilepsy.

GW Pharma Reveals Epidiolex Pricing

Spider venom strikes a blow against childhood epilepsy

A dietitian on what you need to know about the keto diet - Another Fad?

UCLA researcher uses virtual reality to understand how animals perceive space Mayank Mehta’s work has implications for diagnosing and treating neurological diseases

Addressing Psychiatric Comorbidities in Pediatric Epilepsy

Folate May Limit Language Delays in Kids of Epileptic Women

Cognition and Dementia in Older Patients With Epilepsy

Rewiring the brain to fight epilepsy

Can scientists leverage mysterious mossy cells for brain disease treatments?

Long-Term Cannabis Use May Lead To Serious Memory Impairments

Medical Marijuana for Epilepsy: What We Know

Public faith in marijuana outpaces medical research, study finds

Music & Epilepsy

Rare and Unusual Syndromes That May Appear In Epilepsy

Hmmm . . . Iranian scientists claim to develop cure for epilepsy

Cardiac Pathology in SUDEP Compared With Sudden Arrhythmic or Traumatic Deaths

Australian Study Shows That Even Low CBD Extracts Can Treat Epileptic Seizures

Insight without incision: Advances in noninvasive brain imaging offers improvements to epilepsy surgery

Study: Protein found to be key component in irregularly excited brain cells

LivaNova Launches Study to Assess VNS Therapy in Drug-resistant Epilepsy Patients

Locations

Contact